Introduction
Patients affected by acute coronary syndromes (ACS) are at high risk of further ischaemic cardiovascular events both in the short and medium term after discharge. 1, 2 Effective reduction of LDL cholesterol (LDL-C) levels obtained with statin treatment after an ACS has been associated with a substantial decrease in cardiovascular morbidity. 3, 4 In fact, there is undisputed evidence that every statin-induced reduction of LDL-C of about 35-40 mg/dL correlates with a 20-25% decrease in the relative risk of subsequent ischaemic cardiovascular events. 
LDL-C in patients with ACS
The systemic inflammatory response that constantly accompanies an ACS induces major modifications in LDL-C levels, even in the absence of any specific treatment. Clinical studies performed in ACS patients before the dissemination of revascularization procedures have shown the occurrence of a spontaneous 30% reduction of LDL-C during the initial clinical course. 5 Subsequent investigations in ACS patients undergoing pharmacological or mechanical reperfusion have detected less relevant variations, with an average LDL-C reduction of about 10%. 6, 7 Generally, LDL-C levels drop significantly within the first 24 h from admission and reach their minimum in about 7 days from clinical onset. 6, 7 It is therefore appropriate to measure LDL-C as soon as possible in the course of the hospitalization. Such initial values should be considered as a reference point and used to support the choice of pharmacological therapy. In general, average LDL-C values during hospitalisation in 'statin-naive' ACS patients may vary between 120 and 130 mg/dL. 8, 9 Lower values (90-110 mg/dL) are usually detected in patients experiencing an ACS despite an ongoing statin treatment. 8, 9 Recommendations from international guidelines and new evidence from clinical studies
The ESC/EAS joint guidelines on clinical management of dyslipidaemias 10 contain the following indications:
(1) LDL-C is recommended to be used as the primary lipid analysis for screening, risk estimation, diagnosis, and management (recommendation of level I, class of evidence A); besides, LDL-C is recommended as the primary target for treatment (recommendation of level I, class of evidence A). The most recent ESC guidelines on the management of ACS 11 confirm the need for an early treatment with high efficacy statins, which should be effective in reducing LDL-C of at least 50%. 11 The only available statin agents that may possibly achieve such effects are atorvastatin (dosage of 40-80 mg/day) and rosuvastatin (dosage of 20-40 mg/day) 10 ( Table 1 ). In the same guidelines on the management of ACS the goal of reducing LDL-C below 70 mg/dL is also confirmed. 11 In those cases where, despite treatment with the maximum tolerated statin dose, it is not possible to reach the recommended LDL-C target, the addition of ezetimibe to cholesterol lowering therapy should be considered (recommendation of level IIa, class of evidence B).
Ezetimibe is a selective inhibitor of the intestinal absorption of cholesterol, belonging to the class of 2-azetidinones. This drug blocks a critical mediator of cholesterol absorption, the Niemann-Pick C1-like 1 (NPC1L1) protein in brush border of the intestine. 12 In response to reduced cholesterol delivery, the liver reacts by upregulating LDL receptor expression, which in turn leads to an increased clearance of LDL-C from the blood. In clinical studies, ezetimibe in monotherapy has proven effective in reducing LDL-C by 15-22%. The combination of ezetimibe with a statin, which inhibits the hepatic synthesis of cholesterol, determines an interesting therapeutic synergy and provides greater reductions in LDL-C through a dual inhibition of both cholesterol production and absorption. 12 Overall, when added to a statin, ezetimibe provides an incremental reduction in LDL-C levels of 15-20%. 13 In fact, the addition of a standard dose of 10 mg of ezetimibe to a treatment with only 10 mg of atorvastatin produces an overall reduction of LDL-C of about 50%. 13 The recommendations supporting the use of ezetimbe in patients with ACS, which have been recently included in the ESC guidelines, 10, 11 follow the results of the study IMProved Reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
14 In fact, this is the first randomized clinical trial evaluating the efficacy of the combination of ezetimibe (10 mg) and simvastatin (40 mg) in patients with ACS. This combination therapy was compared, in a double-blind fashion, with simvastatin alone (40 mg). The study enrolled 18 144 ACS patients in more than 1000 hospitals in 39 different countries. The patients were included in the study within 10 days from admission and had LDL-C levels below 125 mg/dL. The study had a follow-up lasting on average more than 6 years. The primary endpoint was a composite of cardiovascular mortality, non-fatal myocardial infarction, hospitalization for unstable angina, myocardial revascularization, and nonfatal stroke. As expected, during follow-up, patients treated with the combination of ezetimibe and statin showed a greater reduction in the LDL-C levels as compared with those treated with simvastatin alone. In the simvastatin-ezetimibe group the median LDL-C level during the study was 53.7 mg/dL, as compared with 69.5 mg/dL in the simvastatin-monotherapy group. This significant reduction in LDL-C was associated with a lower incidence of cardiovascular adverse events during follow-up. In fact, patients treated with the association simvastatinezetimibe showed a significant 6.4% reduction in the risk of major adverse cardiovascular events. In terms of individual components of the primary end-point, the event reduction was mainly driven by a statistically significant reduction in the risk of non-fatal myocardial infarction (13% reduction), and non-fatal ischaemic stroke (21% reduction). Overall, there was a significant 10% reduction in the combined risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Finally, in pre-specified subgroup analyses, the benefit of the combination treatment appeared to be particularly pronounced in patients with diabetes mellitus and in elderly patients (75 years).
Management strategies in clinical practice
Patients with ACS require a tailored therapeutic intervention aimed at achieving recommended LDL-C targets. 10, 11 However, it should be emphasized that the results of the IMPROVE IT trial support the idea that more ambitious targets could be considered, especially in patients with higher ischaemic risk (e.g. diabetics). However, in clinical practice, physicians must also take into account all factors possibly favouring the occurrence of side effects and adverse reactions of lipid lowering therapies, bearing in mind that adverse events usually occur when higher doses of statins are used. 
Initiation of treatment during hospitalization for ACS
(1) High efficacy statin therapy should be initiated as soon as possible after admission in 'statin-naïve' ACS patients. The initial statin treatment of choice is represented by atorvastatin with a target does of 80 mg/day. 8, 9 In particular, all patients undergoing percutaneous coronary procedures (PCI) should receive full-dose atorvastatin treatment (80 mg) before the procedure. 16 In medically managed ACS patients, the decision on atorvastatin dosage could take into account initial LDL-C levels, age, and comorbidities. However, when LDL-C exceeds 110 mg/dL, atorvastatin 80 mg/day should always be prescribed. (2) In patients experiencing an ACS during statin therapy, the drug, and dosage in use prior to the event should be considered. In general, atorvastatin at the full dose of 80 mg/day is recommended. Whenever available, on treatment LDL-C levels before admission should be considered for further appropriate statin prescription. Besides, given the high ischaemic risk of these particular patients, it may be necessary to pursue lower LDL-C levels (50-60 mg/dL). Medium-and long-term treatment after discharge 
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adherence to prescribed treatments, as well as occurrence of any adverse reaction to lipid lowering therapy, should be verified during all follow-up visits. (2) In patients who, despite treatment with the maximum tolerated statin dose, do not reach the recommended LDL-C values ezetimibe 10 mg/day should be added. (3) In patients developing mild side effects or adverse reactions during statin treatment, a dose reduction (for example from 80 to 40-20 mg/day of atorvastatin) and the simultaneous addition of ezetimibe 10 mg/day can be implemented. This measure ensures a lower risk of side effects and a higher probability of reaching lipid targets ( Figure 2 ).
